Published in J Clin Endocrinol Metab on January 01, 2011
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Pituitary homeobox 2 (PITX2) promotes thyroid carcinogenesis by activation of cyclin D2. Cell Cycle (2010) 2.29
Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2009) 2.10
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A (2006) 1.62
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes (2010) 1.28
Pancreatic neuroendocrine tumors. Endocr Res (2011) 1.26
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol (2007) 1.20
Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis (2002) 1.18
Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor alpha1 or beta. Mol Endocrinol (2005) 1.12
Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-beta isoform specific and required for adaptive thermogenesis. Endocrinology (2009) 1.06
Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab (2011) 1.05
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proc Natl Acad Sci U S A (2011) 1.00
Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol Cell Biol (2007) 0.99
Thyroid hormone receptors and cancer. Biochim Biophys Acta (2012) 0.99
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res (2012) 0.99
Knock-in mouse model for resistance to thyroid hormone (RTH): an RTH mutation in the thyroid hormone receptor beta gene disrupts cochlear morphogenesis. J Assoc Res Otolaryngol (2002) 0.99
The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis (2006) 0.97
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol (2008) 0.96
Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol (2009) 0.96
Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology (2013) 0.92
Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor. Endocrinology (2012) 0.92
Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRbetaPV knock-in mouse. Psychopharmacology (Berl) (2005) 0.91
Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biol (2004) 0.90
Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology (2010) 0.90
Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors. Mol Endocrinol (2011) 0.88
Characterization of skeletal phenotypes of TRalpha1 and TRbeta mutant mice: implications for tissue thyroid status and T3 target gene expression. Nucl Recept Signal (2006) 0.87
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription. Steroids (2006) 0.86
Novel oncogenic actions of TRbeta mutants in tumorigenesis. IUBMB Life (2009) 0.86
Regulation of fibroblast growth factor receptor-1 (FGFR1) by thyroid hormone: identification of a thyroid hormone response element in the murine Fgfr1 promoter. Endocrinology (2007) 0.84
Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer. Endocrinology (2006) 0.83
Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor β gene due to activation of Wnt/β-catenin protein signaling. J Biol Chem (2012) 0.82
Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models. Thyroid (2013) 0.82
A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant. Hum Mol Genet (2013) 0.81
Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis (2013) 0.81
Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. AIDS (2002) 0.81
Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid (2011) 0.80
The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells. Neoplasia (2008) 0.79
Thyroid hormone receptor α mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice. Endocrinology (2014) 0.79
Three-dimensional telomere dynamics in follicular thyroid cancer. Thyroid (2013) 0.78
Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid (2015) 0.76
Elephantiatic dermopathy. Int J Dermatol (2012) 0.75
Computer modeling of a newly identified THRB gene mutation (S350L) associated with resistance to thyroid hormone in three unrelated patients. Thyroid (2014) 0.75
Familial thyroid neoplasia: impact of technological advances on detection and monitoring. Curr Opin Endocrinol Diabetes Obes (2010) 0.75
Visual vignette. Neurocysticercosis. Endocr Pract (2011) 0.75
Visual vignette. Endocr Pract (2011) 0.75